The CardioMPO™ diagnostic test measures the amount of myeloperoxidase (MPO), a proinflammatory enzyme involved in all stages of the atherosclerotic process. Higher blood levels of MPO indicate the presence of atherosclerotic plaque that is actively progressing towards rupture.
The CardioMPO™ test helps to identify the near-term risk of heart failure and future cardiovascular disease in apparently healthy individuals, or the risk of a second event in patients who have suffered a heart attack.
MPO is a powerful marker when used with, or instead of, other routinely used inflammatory biomarkers such as high sensitivity C-reactive protein. This specific marker of inflammation and of vulnerable plaque, erosions, and fissures, is not likely to be elevated in response to chronic infections or rheumatologic disorders.
To learn more about the CardioMPO™ test, please contact us today!
Heslop et al, 2010. Myeloperoxidase and C-Reactive Protein Have Combined Utility for Long-Term Prediction of Cardiovascular Mortality After Coronary Angiography. Journal of the American College of Cardiology; 55: 1102-1109.
Wong et al, 2009. Myeloperoxidase, Subclinical Atherosclerosis, and Cardiovascular Disease Events. Journal of the American College of Cardiology: Cardiovascular Imaging; 2: 1093-1099.